BioTissue posters spotlight cryopreserved amniotic membrane in complex eye cases

Two case-report posters at the American Academy of Optometry meeting in Anaheim will examine how cryopreserved amniotic membrane was used in difficult ocular surface conditions, including neurotrophic keratitis and herpetic keratitis. The presentations add to clinical discussion around whether CAM can help support healing before surgery and alongside antiviral therapy.

Why it matters: - Complex ocular surface disease can delay surgery, impair vision and make corneal healing harder to achieve. - The case reports add real-world evidence for cryopreserved amniotic membrane as a possible support tool in patients who do not respond well to conventional treatment. - The findings may be relevant for clinicians treating neurotrophic keratitis, herpetic keratitis and other hard-to-manage corneal conditions.

What happened: - Two scientific posters are being presented at the American Academy of Optometry’s annual meeting, Sept. 30-Oct. 3 in Anaheim, Calif. - The posters focus on the use of cryopreserved amniotic membrane, or CAM, in complex ocular surface conditions. - One case report covers neurotrophic keratitis linked to anti-glaucomatous medications. - The other case report covers herpetic keratitis in an immunocompromised patient. - BioTissue President and CEO Ted Davis said the reports show how cryopreserved amniotic membrane is being used in difficult-to-manage cases.

The details: - Amber Carissa “A.C.” Flynn, OD, will present “Preservative Toxicity to Biometric Reliability: Ocular Surface Optimization with Cryopreserved Amniotic Membrane Before Cataract and Glaucoma Surgery.” - The case describes a glaucoma patient with stage 1 neurotrophic keratitis whose ocular surface disease made topography and biometry measurements unreliable before cataract surgery. - Treatment with BioTissue CAM360 AmnioGraft helped resolve corneal staining and improve corneal sensitivity. - The patient was then cleared for biometry and underwent cataract extraction with minimally invasive glaucoma surgery. - Paul Hammond, OD, will present “Use of Antivirals and Cryopreserved Amniotic Membrane to Manage Signs and Symptoms of Herpetic Keratitis.” - The case describes an immunocompromised patient who developed severe herpes simplex virus keratitis and reduced corneal sensitivity after a hospital stay. - Treatment with BioTissue Prokera Slim, along with antiviral and antibiotic therapy, resolved corneal dendrites within two days. - At four-month follow-up, the cornea remained quiet and vision stayed at the pre-infection baseline. - The presentations say CAM may serve as a complementary treatment to antiviral therapy and may help reduce long-term corneal damage after HSV reactivation.

Between the lines: - The posters are aimed at clinicians who manage patients with compromised corneal surfaces before surgery or after infection. - The cases suggest CAM may be most useful when standard approaches are not enough to restore corneal health quickly. - BioTissue is using the conference to reinforce its clinical positioning in ocular surface disease and regenerative healing.

What's next: - The posters will be on display in the Exhibit Hall on Friday, Oct. 2, from 1-3 p.m. - The full program is available here. - BioTissue says it continues to advance multiple Investigational New Drug clinical trials and pursue Biologic License Applications for its products. - The company says clinicians have performed more than 1 million human implants with its products and published 420 peer-reviewed papers supporting its platform technology.

The bottom line: - The posters position cryopreserved amniotic membrane as a potentially useful adjunct in corneal disease cases where healing is difficult and surgical timing matters.